StimCell Energetics Engages Stonegate Capital Partners for Research Coverage and Institutional Investor Outreach

Rhea-AI Summary

StimCell Energetics (OTCQB:STME) engaged Stonegate Capital Partners for research coverage and institutional investor outreach under a 12-month advisory agreement effective March 12, 2026.

The company will issue 250,000 common shares as compensation; shares carry a six-month Canadian hold and are issued under Canadian and U.S. registration exemptions.

Positive

• Secured institutional outreach via Stonegate with global investor relationships
• Paid advisory fee with equity, conserving cash by issuing 250,000 shares

Negative

• Immediate dilution from issuance of 250,000 shares
• Issued shares subject to a six-month hold limiting immediate tradability in Canada

VANCOUVER, BC / ACCESS Newswire / March 19, 2026 / StimCell Energetics Inc. (OTCQB:STME) ("StimCell" or the "Company"), a biotech pioneer targeting cellular energy to enhance wellness, anti-aging, and longevity, is pleased to announce that it has engaged Stonegate Capital Partners, Inc. ("Stonegate") to provide research coverage and institutional investor outreach services.

Pursuant to the Advisory Services Agreement effective March 12, 2026, Stonegate will deliver comprehensive services including quarterly updated research, ongoing investor relations consultation and representation and coordination of targeted institutional investor meetings.

As compensation for the initial twelve-month term, the Company will issue 250,000 shares of its common stock to Stonegate. Stonegate is a leading research and investor outreach firm with over 50 years in business, 100+ clients, and a proven track record of amplifying public company stories to a global audience through best-in-class targeting, analytics, a dedicated sales desk, and relationships with 750 investment firms and 1,250 individual contacts across 15 countries and 35 cities.

"We are happy to partner with Stonegate to elevate our visibility and build institutional ownership," said David Jeffs, CEO of StimCell Energetics. "Their expertise in research coverage and direct outreach to mutual funds, investment managers and family offices will help us share the transformative potential of our eBalance^® technology with a broader investor audience and support our long-term growth objectives."

The shares issued to Stonegate are being issued pursuant to exemptions from the prospectus requirements of applicable Canadian securities laws and will be subject to a six-month hold period from the date of issuance. Such shares may not be traded in or from any jurisdiction in Canada except in compliance with the conditions set forth in Canadian Multilateral Instrument 51-105 Issuers Quoted in the U.S. Over-the-Counter Markets. The shares are also being issued pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws. Such shares may not be offered or sold except pursuant to an effective registration statement or an available exemption from the registration requirements thereof.

About StimCell Energetics Inc.

StimCell Energetics Inc. is a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness and alleviate health complications including, but not limited to: aging, insulin sensitivity, high blood pressure, neuropathy and kidney function. The Company's main focus is on continued research and development of its eBalance^® Technology and its eBalance^® Home System.

On behalf of the Board of Directors of StimCell Energetics Inc.

David Jeffs
CEO, Director

For further information:

info@stimcell.com
www.StimCell.com

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. Except as required by law, StimCell Energetics Inc. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that StimCell Energetics Inc. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.

SOURCE: StimCell Energetics

View the original press release on ACCESS Newswire

FAQ

What did StimCell (STME) announce on March 19, 2026 about investor outreach?

StimCell engaged Stonegate Capital Partners for investor outreach and research coverage. According to the company, the 12-month agreement begins March 12, 2026 and includes quarterly research and targeted institutional meetings to build ownership.

How is Stonegate being compensated by StimCell (STME) for the advisory services?

Stonegate will receive 250,000 common shares as compensation for the initial 12-month term. According to the company, the equity payment preserves cash while securing research and outreach services.

Are the 250,000 shares issued to Stonegate tradable immediately for STME shareholders?

No, the shares are subject to a six-month hold period in Canada and registration exemptions in the U.S. According to the company, the shares cannot be sold except under applicable exemptions or an effective registration.

What services will Stonegate provide to StimCell (STME) under the March 12, 2026 agreement?

Stonegate will provide quarterly updated research, investor relations consultation, representation, and coordination of institutional meetings. According to the company, Stonegate leverages targeting, analytics, and a global sales desk for outreach.

How might the Stonegate engagement affect StimCell's (STME) investor base?

The engagement aims to increase institutional visibility and ownership among funds and family offices. According to the company, Stonegate's network covers 750 firms and 1,250 contacts across 15 countries and 35 cities.